Laston

Quick links to important sections

Laston

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laston

Property Description
Active ingredient Ketorolac tromethamine
Form Oral tablets, injectable solutions, nasal spray, and ophthalmic solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Short-term management of moderately severe acute pain
Origin Synthetic organic compound

Laston is a potent pharmaceutical preparation whose active component is Ketorolac tromethamine, classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). The medication's primary function is the short-term management of acute pain, such as the discomfort typically experienced after surgical procedures. This drug is indicated for the short-term management of moderately severe acute pain that requires analgesia at the opioid level. This capability means the medication can provide relief comparable to some narcotic pain relievers, but it is fundamentally a non-narcotic agent without the associated risk of dependency, a feature specifically designed to act as an opioid-sparing agent.


What Type of Medicine is Laston?

Laston belongs to the NSAID class and is clinically recognized for its powerful analgesic activity, which is its ability to reduce pain sensation. The compound is a synthetic organic compound, derived from heterocyclic acetic acid, and is exclusively available as a prescription-only medication. The mechanism involves inhibiting the synthesis of prostaglandins, which are body chemicals that drive pain, inflammation, and fever.

As a single active ingredient product, Laston contains only Ketorolac tromethamine. The drug is versatile in its presentation, available in several dosage forms, notably the oral tablet and a sterile aqueous injectable solution for parenteral administration. The availability of both parenteral and oral forms, along with specialized presentations like the nasal spray and ophthalmic solution, provides clinicians with flexibility in ensuring continuity of effective pain management.

What side effects are possible with Laston?

Possible Side Effects and Safety Information

The safety profile of Laston (ketorolac tromethamine) is formally documented in regulatory labeling, organizing potential adverse effects by both the System-Organ Class and frequency of occurrence.

Adverse Reaction Classifications

The medicine's documented effects span several organ systems, including the Gastrointestinal, Cardiovascular, Renal, and Nervous systems.

Frequency Category Examples of Officially Listed Effects
Very Common (ge 1/10) Headache, injection site pain (with parenteral forms).
Common (ge 1/100 to <1/10) Nausea, dyspepsia, gastrointestinal pain, dizziness, edema, hypertension.
Rare (<1/1,000) Anaphylaxis, hepatic failure, peptic ulceration.

Serious Adverse Reactions and Safety Constraints

Official labeling explicitly identifies serious adverse reactions, which, though rare, are clinically significant. These include fatal gastrointestinal bleeding and perforation, serious cardiovascular thrombotic events (such as myocardial infarction and stroke), and severe cutaneous reactions like Stevens-Johnson Syndrome (SJS).

Duration and Dose-Related Risk: The risk of serious cardiovascular events may occur early in treatment and increase with the duration of use. Consequently, the incidence and severity of complications are officially noted to increase with both the dose and the duration of treatment, which is limited to five days for combined use.

Population-Specific Safety: Older adults are documented to be at greater risk for serious gastrointestinal events. The medicine is formally contraindicated in patients with advanced renal impairment or suspected cerebrovascular bleeding due to the associated risks.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose of Laston (Ketorolac tromethamine) is derived exclusively from regulatory documents and focuses on documented clinical manifestations and mandated emergency actions. Overdose presentations are commonly characterized by gastrointestinal effects.

Documented Overdose Manifestations

Classification Manifestation
Common Signs Nausea, vomiting, epigastric pain, abdominal pain, lethargy, and drowsiness are typical with acute NSAID overdosage.
Severe Outcomes (Rare) Overdosage has been associated with severe events, including acute renal failure, hypertension, respiratory depression, coma, and the development of peptic ulcers or gastrointestinal bleeding.

Emergency Actions and Management

If an overdose is suspected, it is mandated to seek emergency medical help right away or contact a Poison Control center. Management is restricted to symptomatic and supportive care, as no specific antidotes are known for Ketorolac tromethamine. Though specific procedures like gastric lavage or administration of activated charcoal may be considered within four hours of a significant oral overdose, forced diuresis or dialysis are generally considered unlikely to be beneficial. Symptoms, including renal dysfunction and peptic ulcers, have typically resolved after discontinuation of dosing.

Therapeutic Uses of Laston

What Laston Treats: Main Uses and Benefits

Laston (Ketorolac tromethamine) is a non-opioid used for the short-term management of moderately severe acute pain that requires supportive symptom management where a high level of relief is needed. It is not used for minor aches or long-term conditions.

The medication is commonly used across conditions presenting with acute episodes where discomfort is pronounced, including pain following surgical procedures, dental extractions, and severe episodic crises such as renal colic (kidney stones). It is applied in clinical settings that involve acute or unstable symptom patterns and often during phases when symptoms become more noticeable.

“This approach provides support that helps ease the overall symptom burden during difficult episodes of heightened discomfort.”

Laston helps manage symptoms related to physical discomfort and associated inflammatory or irritative states, which contributes to improved comfort when symptoms interfere with routine activities. It is an option applied in pain management for adult patients requiring non-narcotic relief.


Quick Fact: Relief for Acute Pain Spikes Laston assists with maintaining functional stability by managing pain that requires a high level of symptomatic support and is considered relevant as a non-opioid approach.

Regulatory References

  1. official drug information

Eligibility and Restrictions for Use

Laston is explicitly indicated for use in adults 17 years of age and older for the short-term management of moderately severe acute pain. Official regulatory documents establish strict eligibility rules, primarily based on contraindications designed to mitigate significant risk.

Populations Who Must NOT Use Laston (Contraindications)

Classification Prohibited Population Criteria
Gastrointestinal/Bleeding Patients with active peptic ulcer disease or a history of GI bleeding/perforation; patients with high bleeding risk, including those undergoing CABG surgery.
Organ Function/Allergy Patients with advanced renal impairment (severe kidney disease); patients with known hypersensitivity to ketorolac or other NSAIDs (e.g., aspirin).
Reproductive Status Use during labor and delivery; use during lactation (breastfeeding).

Eligibility Restrictions and Limitations

Restriction Type Official Eligibility Rule
Age Safety and effectiveness are not established in pediatric patients under 17 years of age.
Dosage Restriction Older adults (65 and older) and patients weighing less than 50 kg require a reduced total daily dosage due to altered drug clearance.
Pregnancy Use must be avoided in pregnant women at or after 30 weeks gestation.

What should I know about interactions with other medicines?

The official regulatory profile for Laston (Ketorolac tromethamine) defines specific interactions that are categorized as either formal prohibitions or clinically significant combinations requiring caution. These interactions are based on documented changes to drug exposure or additive pharmacodynamic effects.

Formal Contraindications

Regulatory labels strictly prohibit co-administration with several substances. These include Aspirin and other NSAIDs due to the cumulative pharmacodynamic risk of severe gastrointestinal (GI) events. The drug is also contraindicated with Probenecid, as this combination decreases Laston’s clearance, substantially increasing its plasma exposure. Similarly, use with Lithium and Anticoagulants (such as Warfarin) is prohibited because Laston can decrease Lithium's renal clearance or create an additive hemorrhagic risk, respectively.

Clinically Significant Interactions and Restrictions

Co-administration with ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and Diuretics may increase the risk of renal function deterioration, especially in elderly or volume-depleted patients, and may reduce the efficacy of these blood pressure medications. Combining Laston with SSRIs or Oral Corticosteroids increases the documented risk of GI bleeding. The total duration of Laston use across all formulations (oral, injectable, nasal) must not exceed five days. Oral administration with a high-fat meal may delay the time-to-peak concentration, and concurrent consumption of alcohol is documented to elevate the risk of GI mucosal bleeding.

Mechanism of Action

Targeted Enzyme Inhibition in Prostaglandin Synthesis

This mechanism involves the non-selective inhibition of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. By binding to these targets, the drug blocks the conversion of arachidonic acid into prostanoids . This action is the fundamental molecular step that shapes the drug's downstream effects, classifying it as an inhibitor of prostaglandin synthetase.

Modulation of Nociceptive Signaling Pathways

The suppression of prostaglandin synthesis directly affects nociceptive signaling pathways by diminishing the concentration of mediators that sensitize pain-sensing neurons (nociceptors). The drug's mechanism leads to the dampening of hyperactivity in these peripheral neurons and acts centrally to modulate the transmission of nociceptive signals. This modulation is the core physiological effect that results in the regulation of heightened signaling.

Functional Consequence on Homeostatic Prostanoids

The non-selective action on COX-1, while necessary for the overall effect, results in the simultaneous reduction of homeostatic prostaglandins. This mechanism influences physiological processes such as the maintenance of gastric mucosal integrity, Thromboxane A2-mediated platelet aggregation, and renal blood flow regulation. This effect represents an inherent functional consequence of the drug's mechanism of action.

Dosage and Administration Information

Official Administration Guidelines

Laston (Ketorolac tromethamine) is administered via multiple official routes to ensure flexibility in managing acute pain. The medication is available as an injectable solution for intravenous (IV) or intramuscular (IM) injection, an oral tablet, and an intranasal spray. The overall course of treatment for all systemic forms—IV, IM, and oral—is strictly limited and must not exceed 5 days in total duration.

The usage of the oral tablets is uniquely sequenced within the treatment protocol. Oral tablets are reserved solely for continuation therapy and must not be used to start the treatment course. For multiple-dose IV or IM administration in adults under 65 years and over 50 kg, the typical dose is 30 mg every 6 hours, up to a maximum of 120 mg per day. The oral dose for continuation therapy is generally 10 mg every 4 to 6 hours, with a maximum of 40 mg per day.

Specific procedural requirements govern the administration of the injectable form; for instance, an IV bolus must be administered slowly over no less than 15 seconds. Furthermore, special consideration is given to vulnerable patients. For older adults (65 years and over), those with low body weight, or those with renal impairment, the maximum daily dose for IM or IV administration is reduced to 60 mg per day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Laston (Ketorolac tromethamine)

The clinical evaluation of Laston was studied for decades in research, primarily using short-term, controlled studies that examine its evaluation in conditions involving periods of heightened symptoms. The evidence focuses on its study in acute pain regimens and its evaluation in settings examining the collection of data on narcotic pain reliever consumption.


Evidence for Use in Moderately Severe Acute Pain

This section will outline the structure of clinical research, including Randomized Controlled Trials (RCTs) and meta-analyses, that evaluated Laston in the context of short-term acute pain following surgical and other procedures in adult patients. These studies typically compared patients receiving Laston against those receiving a placebo or other pain options. Researchers monitor patient-reported outcomes describing perceived discomfort using standardized scales, and track how symptoms evolved in the observed populations during the immediate recovery period.


Evidence as an Opioid-Sparing Option

A significant body of evidence, including meta-analyses of multiple RCTs, has explored Laston's administration as a component of multimodal pain studies. The primary goal of this research examined outcomes related to systemic or functional imbalance, specifically focusing on the total dosage of opioid medication consumed by patients.

Findings indicate that when Laston was included in the pain regimen, there was an association with a lower measured consumption of opioid medication over the study intervals. Research also explored outcomes linked to inflammatory or irritative states during this combined approach.


Study Duration and Long-Term Follow-up

The vast majority of research for Laston was evaluated in trials lasting only a few days, consistent with its study context for short-term pain. Due to these short treatment windows, there is limited information for long-term outcomes beyond the immediate acute recovery period. Long-term effects are not fully established through existing controlled research.

Frequently Asked Questions (FAQ)

Common questions about Laston (FAQ)

Q: Is Laston the same kind of drug as [Similar Drug Name]?

A: Official information confirms that Laston (ketorolac tromethamine) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This is a class of medications defined by regulatory bodies for their mechanism of action related to pain and inflammation.

Q: Is Laston available as a generic medicine?

A: Yes. The active component, ketorolac tromethamine, is available as a generic prescription medication. This means the medicine is available under its chemical name (ketorolac tromethamine).

Q: What is the difference between Laston and a supplement for the same condition?

A: Laston is a medication that requires a prescription and is heavily regulated by government health agencies as an NSAID. Supplements are regulated under different criteria and do not undergo the same level of scrutiny or approval process as prescription medications.

Q: Why do some official documents mention a black box warning for Laston?

A: Regulatory documents use a Boxed Warning to call attention to important potential risks. For Laston, this warning highlights the risk of serious gastrointestinal issues (like bleeding or ulcers) and the risk of cardiovascular events (like heart attack or stroke).

Q: Does Laston interact with common over-the-counter pain relievers?

A: Official labeling strictly prohibits combining Laston with aspirin or other NSAIDs (Nonsteroidal Anti-inflammatory Drugs) due to a greater risk of serious side effects. While acetaminophen (a common non-NSAID pain reliever) does not have a formal interaction, all prescribed and non-prescribed medicines should be reviewed with a healthcare provider.

Q: Can I take Laston if I am currently taking an antidepressant?

A: Regulatory information indicates that combining Laston with certain medications, including SSRIs (a type of antidepressant) or oral corticosteroids, may increase the documented risk of gastrointestinal bleeding.

Q: What is the average duration of action or half-life of Laston?

A: The elimination half-life of the active ingredient is approximately 4 to 6 hours in healthy adults. The half-life is the time it takes for half of the drug to be eliminated from the body. Official data indicates that this period may be longer for older adults or individuals with certain health conditions, such as impaired kidney function.

Q: Are there specific times of day that Laston is generally taken?

A: Official dosing focuses on a frequency of administration, such as taking the medicine every 4 to 6 hours, rather than a specific time of day. Official documents also mention that taking the oral form with a high-fat meal may affect the time it takes to reach peak concentration.

Q: How long does it typically take for Laston to start working?

A: According to official product information, the onset of pain relief is often observed within 30 to 60 minutes of administration. The peak effect of the medication generally occurs about 1 to 3 hours after the dose.

Q: What should I do if I miss a scheduled time for Laston?

A: Official patient information often provides guidance for managing a missed dose; however, all administration decisions should align with the instructions provided by the prescribing professional.

Q: Are there any common side effects of Laston that usually go away?

A: Official documents list common side effects that include things like upset stomach, nausea, dizziness, and drowsiness. Any persistent or worsening side effects should be reviewed using the established safety protocols.

Q: Can taking Laston affect my ability to drive or operate machinery?

A: Official safety documents list potential effects such as dizziness, drowsiness, and blurred vision. Patients who experience these effects are generally cautioned regarding activities that require alertness, such as driving or operating machinery.

Q: Is it normal to feel [vague side effect, e.g., tired] when starting Laston?

A: Drowsiness, dizziness, and fatigue are listed among the commonly reported side effects in official documents.

Q: Does Laston have a high risk of dependence or addiction?

A: Official regulatory bodies classify Laston as a non-narcotic agent and it is not a controlled substance. Therefore, it does not carry the same risk of dependence or addiction associated with opioid pain relievers.

Q: Are there any foods or drinks I should avoid while using Laston?

A: Regulatory documents state that the consumption of alcohol should be avoided. This is due to the documented elevated risk of gastrointestinal bleeding when alcohol is combined with Laston.

Q: How long can a person safely stay on Laston treatment?

A: The combined duration of use for all systemic forms of Laston (injectable, oral, and nasal) is strictly limited to 5 days in total. This limitation is a regulatory requirement driven by the increased risk of serious adverse events associated with prolonged use.

Q: Is it safe to take Laston if I have a heart condition?

A: Laston, like other NSAIDs, carries a warning about an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which may be experienced early in the treatment course. It is also contraindicated (prohibited) for pain relief immediately before or after coronary artery bypass graft (CABG) surgery.

Q: What kind of monitoring (e.g., blood tests) might be needed while on Laston?

A: Official documents state that liver function should be monitored for those with a history of liver disease. Additionally, official documentation indicates that monitoring for kidney function may be warranted in at-risk populations.

Q: Why might a person need to switch from Laston to a different medicine?

A: Laston is indicated only for the short-term management of acute pain. Regulatory guidelines define a maximum treatment limit of 5 days, after which a patient must be transitioned to an alternative non-NSAID analgesic.

Q: What percentage of patients in studies experienced the intended effect from Laston?

A: Clinical trials reported that a high percentage of participants, with some studies indicating figures around 80%, experienced adequate pain relief when using Laston for short-term post-operative pain. This evidence is based on patient-reported outcomes from controlled studies.

Q: Is Laston considered a first-line treatment for the condition it addresses?

A: Laston is indicated for the short-term management of moderately severe acute pain that requires analgesia at the opioid level. Official guidance from some bodies suggests that treatment initiation may generally occur in a hospital setting or a closely monitored environment.

Q: What are the restrictions on Laston use for people with severe liver impairment?

A: Official documents advise using Laston with caution in patients with impaired liver function or a history of liver disease. Due to the potential for serious side effects, the medicine is often avoided in those with advanced liver disease.

Q: Does Laston cause weight gain or weight loss?

A: While direct weight change is not commonly listed, official adverse reaction data includes edema, which is fluid retention or swelling. This documented side effect can sometimes lead to an unusual or sudden weight gain.

Q: What are the general expectations about the onset/duration of Laston's effects?

A: The onset of pain relief is typically observed within 30 to 60 minutes. Given that the drug is generally dosed every 4 to 6 hours for ongoing pain management, this period aligns with its expected duration of action.

How should Laston be stored and disposed of?

The official labeling for Laston (Ketorolac tromethamine) defines specific conditions for storage and disposal to ensure product integrity and safety.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature, generally 20 C to 25 C (68 F to 77 F).
Handling Protect from light; store away from excessive heat. Do not freeze the injectable forms.
Container Keep in the original container, tightly closed, and protect from moisture.
Child Safety Store out of the sight and reach of children.
Stability Certain opened forms, such as the nasal spray, have an in-use stability limit and must be discarded 24 hours after the first use.

Disposal Requirements

Unused or expired Laston must be disposed of according to local regulatory guidelines. The product should not be disposed of in wastewater, such as flushing it down the toilet or pouring it down a drain, to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Laston found in:

A-Z Index: